A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  McCloskey, Curtis W ^a,b   Goldberg, Reuben L ^a,b   Carter, Lauren E ^a,b   Gamwell, Lisa F ^a,b   Al Hujaily, Ensaf M ^a,b   Collins, Olga ^a,b   Macdonald, Elizabeth A ^a,b   Garson, Kenneth ^a,b   Daneshmand, Manijeh ^b,c   Carmona, Euridice ^d   Vanderhyden, Barbara C ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

High grade serous cancer; Mouse model of ovarian cancer; Ovarian cancer; Ovarian surface epithelium; Stem cell; Syngeneic; Tumor initiating cell

Indexed keywords

ATAXIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER MODEL; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME ANALYSIS; COLONY FORMATION; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; DOWN REGULATION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVARY CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84901020255     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00053     Document Type: Article

References (65)

1. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al. Cancer Incidence in Five Continents. (Vol. X). Lyon: IARC (2012). Available from: http://ci5.iarc.fr.
2. Auersperg N. Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis? Gynecol Oncol (2013) 130:246-51. doi:10.1016/j.ygyno.2013.03.021.
3. Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett (2013) 338:147-57. doi:10.1016/j.canlet.2012.10.023.
4. Flesken-Nikitin A, Hwang C-I, Cheng C-Y, Michurina TV, Enikolopov G, Nikitin AY. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature (2013) 495:241-5. doi:10.1038/nature11979.
5. Garson K, Gamwell LF, Pitre EM, Vanderhyden BC. Technical challenges and limitations of current mouse models of ovarian cancer. J Ovarian Res (2012) 5:39. doi:10.1186/1757-2215-5-39.
6. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 195:451-6. doi:10.1002/path.1000.
7. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 211:26-35. doi:10.1002/path.2091.
8. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol (2008) 27:1-9. doi:10.1097/pgp.0b013e31814b191f.
9. Jones PM, Drapkin R. Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms. Front Oncol (2013) 3:217. doi:10.3389/fonc.2013.00217.
10. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, et al. Epithelial ovarian cancer experimental models. Oncogene (2013). doi:10.1038/onc.2013.321.
11. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 16:2045-57. doi:10.1101/gad.993902.
12. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell (2004) 6:171-83. doi:10.1016/j.ccr.2004.07.009.
13. Stammer K, Edassery SL, Barua A, Bitterman P, Bahr JM, Hales DB, et al. Selenium-binding protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer. Gynecol Oncol (2008) 109:115-21. doi:10.1016/j.ygyno.2007.12.030.
14. Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, et al. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. Int J Gynecol Cancer (2009) 19:531-9. doi:10.1111/IGC.0b013e3181a41613.
15. Kulkarni-Datar K, Orsulic S, Foster R, Rueda BR. Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo. Cancer Lett (2013) 339:237-46. doi:10.1016/j.canlet.2013.06.014.
16. Sengupta A, Cancelas JA. Cancer stem cells: a stride towards cancer cure? J Cell Physiol (2010) 225:7-14. doi:10.1002/jcp.22213.
17. Yi S-Y, Hao Y-B, Nan K-J, Fan T-L. Cancer stem cells niche: a target for novel cancer therapeutics. Cancer Treat Rev (2013) 39:290-6. doi:10.1016/j.ctrv.2012.10.004.
18. Gamwell LF, Collins O, Vanderhyden BC. The mouse ovarian surface epithelium contains a population of LY6A (SCA-1) expressing progenitor cells that are regulated by ovulation-associated factors. Biol Reprod (2012) 87:80-80. doi:10.1095/biolreprod.112.100347.
19. Padilla-Nash HM, McNeil NE, Yi M, Nguyen Q-T, Hu Y, Wangsa D, et al. Aneuploidy, oncogene amplification and epithelial to mesenchymal transition define spontaneous transformation of murine epithelial cells. Carcinogenesis (2013) 34:1929-39. doi:10.1093/carcin/bgt138.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013.
21. Amsterdam A, Shezen E, Raanan C, Slilat Y, Ben-Arie A, Prus D, et al. Epiregulin as a marker for the initial steps of ovarian cancer development. Int J Oncol (2011) 39:1165-72. doi:10.3892/ijo.2011.1123.
22. Zhao G, Chen J, Deng Y, Gao F, Zhu J, Feng Z, et al. Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells. Biochem Biophys Res Commun (2011) 408:154-9. doi:10.1016/j.bbrc.2011.03.140.
23. Quinn MCJ, Filali-Mouhim A, Provencher DM, Mes-Masson A-M, Tonin PN. Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol Carcinog (2009) 48:648-61. doi:10.1002/mc.20511.
24. Scurr LL, Guminski AD, Chiew Y-E, Balleine RL, Sharma R, Lei Y, et al. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Clin Cancer Res (2008) 14:6924-32. doi:10.1158/1078-0432.CCR-07-5189.
25. Walker G, MacLeod K, Williams ARW, Cameron DA, Smyth JF, Langdon SP. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res (2007) 13:1438-44. doi:10.1158/1078-0432.CCR-06-2245.
26. Deng B, Zhang S, Miao Y, Han Z, Zhang X, Wen F, et al. Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin a5β1 and phosphorylating FAK and paxillin. J Exp Clin Cancer Res (2012) 31:19. doi:10.1186/1756-9966-31-19.
27. Chen L-M, Wang W, Lee J-C, Chiu F-H, Wu C-T, Tai C-J, et al. Thrombomodulin mediates the progression of epithelial ovarian cancer cells. Tumour Biol (2013) 34:3743-51. doi:10.1007/s13277-013-0958-x.
28. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer (2006) 119:1338-44. doi:10.1002/ijc.22025.
29. Auersperg N. The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae. Int J Gynecol Pathol (2013) 32:444-53. doi:10.1097/PGP.0b013e3182800ad5.
30. Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, et al. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal (2010) 22:926-35. doi:10.1016/j.cellsig.2010.01.017.
31. Nakamura K, Igarashi K, Ohkawa R, Yokota H, Masuda A, Nakagawa S, et al. Serum autotaxin is not a useful biomarker for ovarian cancer. Lipids (2012) 47:927-30. doi:10.1007/s11745-012-3691-0.
32. Urzúa U, Roby KF, Gangi LM, Cherry JM, Powell JI, Munroe DJ. Transcriptomic analysis of an in vitro murine model of ovarian carcinoma: functional similarity to the human disease and identification of prospective tumoral markers and targets. J Cell Physiol (2006) 206:594-602. doi:10.1002/jcp.20522.
33. Rho SB, Dong SM, Kang S, Seo S-S, Yoo CW, Lee DO, et al. Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis. Carcinogenesis (2008) 29:2106-11. doi:10.1093/carcin/bgn206.
34. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol (2006) 19:1149-56. doi:10.1038/modpathol.3800637.
35. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474:609-15. doi:10.1038/nature10166.
36. Hashimoto T, Yanaihara N, Okamoto A, Nikaido T, Saito M, Takakura S, et al. Cyclin D1 predicts the prognosis of advanced serous ovarian cancer. Exp Ther Med (2011) 2:213-9. doi:10.3892/etm.2011.194.
37. Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N. Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med (2012) 4:1092-6. doi:10.3892/etm.2012.715.
38. Hunter SM, Gorringe KL, Christie M, Rowley SM, Bowtell DD. Australian Ovarian Cancer Study Group, Campbell IG: pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res (2012) 18:5267-77. doi:10.1158/1078-0432.CCR-12-1103.
39. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, et al. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One (2011) 6:e28250. doi:10.1371/journal.pone.0028250.
40. Soslow RA. Histologic subtypes of ovarian carcinoma. Int J Gynecol Pathol (2008) 27:161-74. doi:10.1097/PGP.0b013e31815ea812.
41. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 1:53-62. doi:10.1016/S1535-6108(01)00002-2.
42. Xing D, Orsulic S. A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma. Cancer Res (2006) 66:8949-53. doi:10.1158/0008-5472.CAN-06-1495.
43. Testa JR, Getts LA, Salazar H, Liu Z, Handel LM, Godwin AK, et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res (1994) 54:2778-84.
44. Rose GS, Tocco LM, Granger GA, DiSaia PJ, Hamilton TC, Santin AD, et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol (1996) 175:593-9. doi:10.1053/ob.1996.v175.a73595.
45. Lv L, Zhang T, Yi Q, Huang Y, Wang Z, Hou H, et al. Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells. Cell Cycle (2012) 11:2864-75. doi:10.4161/cc.21196.
46. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (2000) 21:585-91. doi:10.1093/carcin/21.4.585.
47. Urzúa U, Best L, Munroe DJ. Microarray proteomic analysis discriminates tumorigenic mouse ovarian surface epithelial cells of divergent aggressive potential. Mol Biosyst (2010) 6:2521-8. doi:10.1039/c005220e.
48. Roberts PC, Mottillo EP, Baxa AC, Heng HHQ, Doyon-Reale N, Gregoire L, et al. Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model. Neoplasia (2005) 7:944-56. doi:10.1593/neo.05358.
49. Ricci F, Broggini M, Damia G. Revisiting ovarian cancer preclinical models: implications for a better management of the disease. Cancer Treat Rev (2013) 39:561-8. doi:10.1016/j.ctrv.2013.01.005.
50. Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol (2013) 44:2373-84. doi:10.1016/j.humpath.2013.05.001.
51. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther (2004) 10:1032-42. doi:10.1016/j.ymthe.2004.08.013.
52. Greenaway J, Moorehead R, Shaw P, Petrik J. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol (2008) 108:385-94. doi:10.1016/j.ygyno.2007.10.035.
53. Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol (2008) 26:3259-67. doi:10.1200/JCO.2007.11.3902.
54. Haraldson K, Kashuba VI, Dmitriev AA, Senchenko VN, Kudryavtseva AV, Pavlova TV, et al. LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication. Biochimie (2012) 94:1151-7. doi:10.1016/j.biochi.2012.01.019.
55. Pharoah PDP, Tsai Y-Y, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 45:e1-2. doi:10.1038/ng.2564.
56. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 42:874-9. doi:10.1038/ng.668.
57. Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, et al. Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. Prostate (2012) 72:1295-305. doi:10.1002/pros.22478.
58. Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 17:4052-62. doi:10.1158/1078-0432.CCR-10-3021.
59. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, Tsao S-W, et al. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci (2004) 95:741-4. doi:10.1111/j.1349-7006.2004.tb03255.x.
60. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 65:8961-7. doi:10.1158/0008-5472.CAN-05-1187.
61. Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer (2011) 128:2063-74. doi:10.1002/ijc.25554.
62. Tapper J, Kettunen E, El-Rifai W, Seppälä M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet (2001) 128:1-6. doi:10.1016/S0165-4608(01)00386-7.
63. Curley DP, Bosenberg MW. A new mechanism of release from senescence: suppression of p16INK4a by beta-catenin. Pigment Cell Melanoma Res (2008) 21:5-6. doi:10.1111/j.1755-148X.2007.00434.x.
64. Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M, et al. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res (2005) 65:8118-24. doi:10.1158/0008-5472.CAN-04-4562.
65. Touma SE, Perner S, Rubin MA, Nanus DM, Gudas LJ. Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem Pharmacol (2009) 78:1127-38. doi:10.1016/j.bcp.2009.06.022.